# Phase 2 Hepatitis B trials recruiting: 24 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 24 trials in phase 2 for Hepatitis B that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Hepatitis B trials: 24 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/hepatitis-b

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 24
- Recruiting or not yet: 24
- Read on: November 19, 2026

## Trials

The 24 newest of 24, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07933627 | Clinical Study of YKYY013 Injection in HBeAg-negative Chronic Hepatitis B Virus-infected Patients Treated With Nucleos(t)Ide Analogues | Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. | Phase 2 | Not yet recruiting | HBV (Hepatitis B Virus) | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07933627) |
| November 5, 2026 | NCT07917910 | A Study of HT-101 and HT-102 in Chronic Hepatitis B (CHB) | Suzhou HepaThera Biotech Co., Ltd. | Phase 2 | Not yet recruiting | Chronic Hepatitis B Virus Infection | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917910) |
| October 1, 2026 | NCT07852091 | A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (A) | The Second Affiliated Hospital of Chongqing Medical University | Phase 2 | Recruiting | Chronic Hepatitis B | 1,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07852091) |
| September 28, 2026 | NCT07845058 | A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (B) | The Second Affiliated Hospital of Chongqing Medical University | Phase 2 | Recruiting | Chronic Hepatitis B, Anti-PD-1 Antibody, Anti-PD-L1 Antibody, Peg-IFNα | 1,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845058) |
| July 16, 2026 | NCT07709520 | Study of GST-HG131&141 Tablets Compared With Placebo in Patients With Chronic Hepatitis B | Fujian Akeylink Biotechnology Co., Ltd. | Phase 2 | Recruiting | Chronic Hepatitis B | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07709520) |
| July 10, 2026 | NCT07696520 | Bepirovirsen Liver Biopsy Study | National University Health System, Singapore | Phase 2 | Not yet recruiting | HEPATITIS B CHRONIC, Hepatitis B Chronic Infection | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07696520) |
| June 17, 2026 | NCT07654283 | Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions | AusperBio Therapeutics Inc. | Phase 2 | Recruiting | Hepatitis B, Chronic | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07654283) |
| June 9, 2026 | NCT07635186 | A Study to Evaluate AHB-137 Injection in Treatment-naïve Participants With Chronic Hepatitis B | Ausper Biopharma Co., Ltd. | Phase 2 | Recruiting | Chronic Hepatitis B | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07635186) |
| June 5, 2026 | NCT07630727 | Study of AHB-171 in Chronic Hepatitis B Participants | Ausper Biopharma Co., Ltd. | Phase 2 | Recruiting | Hepatitis B, Chronic (CHB) | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07630727) |
| April 9, 2026 | NCT07519330 | Clinical Study to Evaluate the Efficacy and Safety of HH-006 in Patients With Chronic Hepatitis B Virus Infection | Huahui Health | Phase 2 | Recruiting | Chronic Hepatitis B Virus Infection | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07519330) |
| January 27, 2026 | NCT07370207 | Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region | AusperBio Therapeutics Inc. | Phase 2 | Recruiting | Hepatitis B, Chronic | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07370207) |
| December 5, 2025 | NCT07267208 | A Prospective Study to Evaluate the Efficacy and Safety of Entecavir ODT Conversion in Stable Liver Transplant Patients | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Hepatitis B Virus, Liver Transplant | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07267208) |
| August 28, 2025 | NCT07145268 | Zinc Sulphate in Treatment Fibrosis in HBV Patient Receiving Antiviral Therapy | Tanta University | Phase 2 | Not yet recruiting | Liver Fibroses, HBV (Hepatitis B Virus) | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07145268) |
| August 22, 2025 | NCT07137910 | A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB) | Ausper Biopharma Co., Ltd. | Phase 2 | Recruiting | Chronic Hepatitis B | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07137910) |
| July 16, 2025 | NCT07069569 | A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs | Ausper Biopharma Co., Ltd. | Phase 2 | Recruiting | Chronic Hepatitis B | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07069569) |
| October 21, 2024 | NCT06650852 | A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic... | Brii Biosciences Limited | Phase 2 | Recruiting | Chronic Hepatitis B Virus (HBV) Infection | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06650852) |
| September 19, 2024 | NCT06589518 | To Evaluate the Efficacy and Safety of Tenofovir Alafenamide Conversion in Liver Transplant Patients | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Hepatitis B Virus, Liver Transplant, Renal Insufficiency | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06589518) |
| May 22, 2024 | NCT06425341 | A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination... | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | Chronic Hepatitis B | 369 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06425341) |
| February 16, 2024 | NCT06263959 | A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in... | Fujian Akeylink Biotechnology Co., Ltd. | Phase 2 | Recruiting | Chronic Hepatitis B | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06263959) |
| January 22, 2024 | NCT06216470 | Vaccinal Effect of HBsAg Monoclonal Ab VIR-3434 in Chronic Hepatitis B Infection \[VISION\] | University Health Network, Toronto | Phase 2 | Recruiting | Hepatitis B, Chronic | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06216470) |
| December 4, 2023 | NCT06154278 | Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B | University of Maryland, Baltimore | Phase 2 | Recruiting | Chronic Hepatitis B | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06154278) |
| March 16, 2023 | NCT05771402 | A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B) | The Second Affiliated Hospital of Chongqing Medical University | Phase 2 | Recruiting | Chronic Hepatitis b, Anti-PD-1 Antibody, Peg-IFNα | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05771402) |
| March 15, 2023 | NCT05769816 | A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A) | The Second Affiliated Hospital of Chongqing Medical University | Phase 2 | Recruiting | Chronic Hepatitis b, Anti-PD-1 Antibody | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05769816) |
| January 18, 2022 | NCT05195294 | Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC | Lion TCR Pte. Ltd. | Phase 2 | Not yet recruiting | Hepatocellular Carcinoma, Liver Cancer, Adult, Liver Cell Carcinoma | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05195294) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| The Second Affiliated Hospital of Chongqing Medical University | 4 |
| Ausper Biopharma Co., Ltd. | 4 |
| Fujian Akeylink Biotechnology Co., Ltd. | 2 |
| AusperBio Therapeutics Inc. | 2 |
| Huahui Health | 1 |
| Tanta University | 1 |
| University Health Network, Toronto | 1 |
| Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. | 1 |
| Lion TCR Pte. Ltd. | 1 |
| [Fujian Shengdi Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/fujian-shengdi-pharmaceutical-co-ltd) | 1 |
| Suzhou HepaThera Biotech Co., Ltd. | 1 |
| University of Maryland, Baltimore | 1 |
| Brii Biosciences Limited | 1 |
| National University Health System, Singapore | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 15 |
| Canada | 2 |
| United States | 2 |
| Singapore | 2 |
| Australia | 1 |
| Japan | 1 |
| New Zealand | 1 |
| South Korea | 1 |
| Taiwan | 1 |
| France | 1 |
| Italy | 1 |
| Spain | 1 |
| United Kingdom | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Drive thru bars in the United States](https://specstream.ai/data/businesses/drive-thru-bars/united-states)
- [Pubs in the United States](https://specstream.ai/data/businesses/pubs/united-states)
- [Contract law firms in the United States](https://specstream.ai/data/businesses/contract-law-firms/united-states)
- [Pizza restaurants in the United States](https://specstream.ai/data/businesses/pizza-restaurants/united-states)
- [Carpenters in the United States](https://specstream.ai/data/businesses/carpenters/united-states)
- [Oral and maxillofacial surgery practices in the United States](https://specstream.ai/data/businesses/oral-and-maxillofacial-surgery-practices/united-states)
